organization · Reporting owner

TAKEDA PHARMACEUTICAL CO LTD

Disclosed activity across 13 companies

Tapewire entity: 2662
SEC CIK: 0001395064

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Calithera Biosciences, Inc.CALA · Entity 113073	Former 10% Owner	April 17, 2023	May 26, 2023
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	10% owner	July 17, 2019	July 17, 2019
Molecular Templates, Inc.MTEM · Entity 85987	10% owner	August 01, 2017	September 08, 2017
Myovant Sciences Ltd.MYOV · Entity 115677	10% owner	March 19, 2018	March 21, 2018
Ovid Therapeutics Inc.OVID · Entity 5411	10% owner	December 08, 2025	December 09, 2025
Quince Therapeutics, Inc.CRTX · Entity 7403	10% owner	May 13, 2019	May 13, 2019
Tessera Defense & Homeland Security Inc.PHGE · Entity 8384	10% owner	October 28, 2019	November 05, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Calithera Biosciences, Inc.

Report date April 17, 2023 · Filed May 26, 2023

Jointly reported with Takeda Ventures, Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.08	IndirectSee Explanation of Responses	0	Reported balance After 2023-04-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-04-17 · Other · Disposed 1,000,000 · Balance 0 F1: The Series A preferred stock (the "Preferred Stock") of Calithera Biosciences, Inc. ("Calithera") was convertible at the option of holder into 857,844 shares of common stock of Calithera ("Common Stock") at a conversion price per share of $40.08, subject to price-based anti-dilution adjustments which, if triggered, would result in additional shares of Common Stock being issued upon conversion of the Preferred Stock. F2: The reported securities were redeemed by the Issuer for the following consideration (in the aggregate, the "Repurchase Price"): (i) $4.0 million in aggregate cash consideration, (ii) a right to receive certain securities held by the Issuer and (iii) a contingent value right entitling Takeda Ventures, Inc. ("TVI") to receive all the remaining proceeds from the sale of the Issuer's assets (not to exceed the Repurchase Price Limit), after establishing a reserve, which will be used to pay all expenses and other known, non-contingent liabilities and obligations, and includes reasonable provision for future expenses of liquidation and contingent and unknown liabilities as required by Delaware law. F3: Notwithstanding the foregoing footnote 2, TVI agreed that if the holders of the Common Stock approved the Plan of Dissolution at a special meeting before June 30, 2023, then the Issuer could distribute up to $0.40 per share in a common stock liquidating distribution to the holders of Common Stock prior to any future distribution to Takeda pursuant to the contingent value right. For the avoidance of doubt, if the holders of Common Stock do not approve the Issuer's Plan of Dissolution at a special meeting before June 30, 2023, then the Issuer will not make the aforementioned common stock liquidating distribution to the holders of Common Stock. In no event shall the Repurchase Price exceed a total value of $35 million (the "Repurchase Price Limit"). F4: The Series A convertible preferred stock has no expiration date. F5: The Preferred Stock was directly held by TVI, a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A preferred stock (the "Preferred Stock") of Calithera Biosciences, Inc. ("Calithera") was convertible at the option of holder into 857,844 shares of common stock of Calithera ("Common Stock") at a conversion price per share of $40.08, subject to price-based anti-dilution adjustments which, if triggered, would result in additional shares of Common Stock being issued upon conversion of the Preferred Stock.

F2: The reported securities were redeemed by the Issuer for the following consideration (in the aggregate, the "Repurchase Price"): (i) $4.0 million in aggregate cash consideration, (ii) a right to receive certain securities held by the Issuer and (iii) a contingent value right entitling Takeda Ventures, Inc. ("TVI") to receive all the remaining proceeds from the sale of the Issuer's assets (not to exceed the Repurchase Price Limit), after establishing a reserve, which will be used to pay all expenses and other known, non-contingent liabilities and obligations, and includes reasonable provision for future expenses of liquidation and contingent and unknown liabilities as required by Delaware law.

F3: Notwithstanding the foregoing footnote 2, TVI agreed that if the holders of the Common Stock approved the Plan of Dissolution at a special meeting before June 30, 2023, then the Issuer could distribute up to $0.40 per share in a common stock liquidating distribution to the holders of Common Stock prior to any future distribution to Takeda pursuant to the contingent value right. For the avoidance of doubt, if the holders of Common Stock do not approve the Issuer's Plan of Dissolution at a special meeting before June 30, 2023, then the Issuer will not make the aforementioned common stock liquidating distribution to the holders of Common Stock. In no event shall the Repurchase Price exceed a total value of $35 million (the "Repurchase Price Limit").

F4: The Series A convertible preferred stock has no expiration date.

F5: The Preferred Stock was directly held by TVI, a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.

Mirum Pharmaceuticals, Inc.

Report date July 17, 2019 · Filed July 17, 2019

Jointly reported with Shire International GmbH

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,859,151	Reported balance Holding disclosure · report date 2019-07-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,859,151 F1: These shares are owned directly by Shire International GmbH, which is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"). Shire International GmbH is a direct, wholly owned subsidiary of Shire Pharmaceuticals International UC, which is a direct subsidiary of Shire Holdings Luxembourg Sarl (60.04%), Shire Ireland Investment Ltd. (28.27%) and Shire Human Genetic Therapies Inc. (11.69%). Shire Human Genetic Therapies Inc. is a direct, wholly owned subsidiary of Shire Holdings US AG, which is a direct, wholly owned subsidiary of Shire Biopharmaceuticals Holdings Ireland Limited, which is a direct, wholly owned subsidiary of Shire North American Group Inc. Each of Shire Holdings Luxembourg Sarl, Shire Ireland Investment Ltd. and Shire North American Group Inc. is a direct, wholly owned subsidiary of Shire Pharmaceutical Holdings Ireland Limited, which is a direct, wholly owned subsidiary of Shire Limited, which is a direct, wholly owned subsidiary of Takeda.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are owned directly by Shire International GmbH, which is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"). Shire International GmbH is a direct, wholly owned subsidiary of Shire Pharmaceuticals International UC, which is a direct subsidiary of Shire Holdings Luxembourg Sarl (60.04%), Shire Ireland Investment Ltd. (28.27%) and Shire Human Genetic Therapies Inc. (11.69%). Shire Human Genetic Therapies Inc. is a direct, wholly owned subsidiary of Shire Holdings US AG, which is a direct, wholly owned subsidiary of Shire Biopharmaceuticals Holdings Ireland Limited, which is a direct, wholly owned subsidiary of Shire North American Group Inc. Each of Shire Holdings Luxembourg Sarl, Shire Ireland Investment Ltd. and Shire North American Group Inc. is a direct, wholly owned subsidiary of Shire Pharmaceutical Holdings Ireland Limited, which is a direct, wholly owned subsidiary of Shire Limited, which is a direct, wholly owned subsidiary of Takeda.

Molecular Templates, Inc.

Report date August 01, 2017 · Filed September 08, 2017

Jointly reported with MILLENNIUM PHARMACEUTICALS INC, Takeda Pharmaceuticals International AG, Takeda Pharma A/S, Takeda A/S, Takeda Europe Holdings B.V., Takeda Pharmaceuticals U.S.A., Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,922,993	Reported balance Holding disclosure · report date 2017-08-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,922,993 F1: These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Myovant Sciences Ltd.

Report date March 19, 2018 · Filed March 21, 2018

Jointly reported with Takeda Pharmaceuticals International AG, Takeda A/S, Takeda Europe Holdings B.V., Takeda Pharma A/S

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-03-19 · Sale · Disposed 7,420,625 · Balance 0 F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Millennium Pharmaceuticals , Inc.	7,420,625	Reported balance After 2018-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-03-19 · Purchase · Acquired 7,420,625 · Balance 7,420,625 F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC.

F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.

Ovid Therapeutics Inc.

Report date December 08, 2025 · Filed December 09, 2025

Jointly reported with Takeda Pharmaceuticals U.S.A., Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Explanation of Responses	7,000,000	Reported balance After 2025-12-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-08 · Conversion · Acquired 1,250,000 · Balance 7,000,000 F1: Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA. F2: The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Explanation of Responses	0	Reported balance After 2025-12-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-08 · Conversion · Disposed 1,250 · Balance 0 F1: Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA. F3: The Preferred Stock had no expiration date. F2: The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.
Common StockSEC Table I · non-derivative	Direct	1,781,996	Reported balance Holding disclosure · report date 2025-12-08 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,781,996

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.

F2: The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.

F3: The Preferred Stock had no expiration date.

Quince Therapeutics, Inc.

Report date May 13, 2019 · Filed May 13, 2019

Jointly reported with Takeda Ventures, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,679,802	Reported balance After 2019-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-05-13 · Conversion · Acquired 2,679,802 · Balance 2,679,802 F1: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock. F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-05-13 · Conversion · Disposed 2,360,071 · Balance 0 F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-05-13 · Conversion · Disposed 319,731 · Balance 0 F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Filing footnotes · ownership attribution and instrument terms

F1: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.

F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Tessera Defense & Homeland Security Inc.

Report date October 28, 2019 · Filed November 05, 2019

Jointly reported with Takeda Ventures, Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,470,935	Reported balance Holding disclosure · report date 2019-10-28 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,470,935 F1: Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of 2,470,935 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Filing footnotes · ownership attribution and instrument terms

F1: Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of 2,470,935 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Day One Biopharmaceuticals, Inc.

Report date December 07, 2021 · Filed December 09, 2021

Jointly reported with Takeda Pharmaceuticals U.S.A., Inc., MILLENNIUM PHARMACEUTICALS INC, Takeda Ventures, Inc.

Section 16 reporting ended · disclosed 2021-12-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Explanation of Responses	6,120,124	Last balance in matching sequence After 2021-12-08 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2021-12-07 · Sale · Disposed 128,745 · Balance 6,288,652 F1: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. F3: Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). F4: Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein. Row 2 · 2021-12-07 · Sale · Disposed 58,190 · Balance 6,230,462 F5: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $19.00 to $19.88. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. F3: Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). F4: Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein. Row 3 · 2021-12-08 · Sale · Disposed 110,338 · Balance 6,120,124 F6: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.47. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. F3: Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). F4: Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc.

F3: Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%).

F4: Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein.

F5: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $19.00 to $19.88. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

F6: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.47. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

HilleVax, Inc.

Report date September 17, 2025 · Filed September 19, 2025

Jointly reported with Takeda Vaccines, Inc.

Section 16 reporting ended · disclosed 2025-09-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Explanation of Responses	0	Reported balance After 2025-09-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-17 · Other · Disposed 6,724,000 · Balance 0 F1: These shares were sold pursuant to the cash tender offer (the "Tender Offer") by XOMA Royalty Corporation, a Nevada corporation ("Parent") and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of Parent, to purchase all of the outstanding shares of common stock of the Issuer at an offer price of (i) $1.95 per share of common stock and (ii) one non-transferable contractual contingent value right. The Tender Offer expired as scheduled at one minute after 11:59 p.m., Eastern Time, on September 15, 2025 (the "Expiration Time") and closing of the Tender Offer was announced on September 17, 2025. As all conditions to the Tender Offer were satisfied or waived, on September 17, 2025, Parent irrevocably accepted for payment all shares validly tendered into and not validly withdrawn from the Tender Offer and paid for all such shares in accordance with the Tender Offer. F2: Takeda Pharmaceutical Company Limited has beneficial ownership of the reported securities, all of which are held directly by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were sold pursuant to the cash tender offer (the "Tender Offer") by XOMA Royalty Corporation, a Nevada corporation ("Parent") and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of Parent, to purchase all of the outstanding shares of common stock of the Issuer at an offer price of (i) $1.95 per share of common stock and (ii) one non-transferable contractual contingent value right. The Tender Offer expired as scheduled at one minute after 11:59 p.m., Eastern Time, on September 15, 2025 (the "Expiration Time") and closing of the Tender Offer was announced on September 17, 2025. As all conditions to the Tender Offer were satisfied or waived, on September 17, 2025, Parent irrevocably accepted for payment all shares validly tendered into and not validly withdrawn from the Tender Offer and paid for all such shares in accordance with the Tender Offer.

F2: Takeda Pharmaceutical Company Limited has beneficial ownership of the reported securities, all of which are held directly by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Phathom Pharmaceuticals, Inc.

Report date January 24, 2024 · Filed January 25, 2024

Section 16 reporting ended · disclosed 2024-01-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,755,583	Reported balance After 2024-01-24 transaction · row 1 1 source row Row 1 · 2024-01-24 · Sale · Disposed 3,703,703 · Balance 3,755,583

Theseus Pharmaceuticals, Inc.

Report date October 12, 2021 · Filed October 15, 2021

Jointly reported with ARIAD PHARMACEUTICALS INC

Section 16 reporting ended · disclosed 2021-10-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee explanation	1,615,427	Reported balance After 2021-10-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-10-12 · Conversion · Acquired 1,615,427 · Balance 1,615,427 F1: Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. F3: The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee explanation	0	Reported balance After 2021-10-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-12 · Conversion · Disposed 1,615,427 · Balance 0 F1: Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. F3: The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc.

F3: The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Translate Bio, Inc.

Report date June 30, 2020 · Filed June 30, 2020

Jointly reported with Shire Human Genetic Therapies, Inc.

Section 16 reporting ended · disclosed 2020-06-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-06-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-06-30 · Sale · Disposed 6,824,992 · Balance 0 F1: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F2: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.

Filing footnotes · ownership attribution and instrument terms

F1: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.

F2: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.

Xilio Therapeutics, Inc.

Report date October 26, 2021 · Filed October 27, 2021

Jointly reported with Takeda Ventures, Inc.

Section 16 reporting ended · disclosed 2021-10-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee explanation	1,475,121	Reported balance After 2021-10-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-10-26 · Conversion · Acquired 1,475,121 · Balance 1,475,121 F1: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc. F3: The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee explanation	0	Reported balance After 2021-10-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-26 · Conversion · Disposed 1,248,180 · Balance 0 F1: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc. F3: The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee explanation	0	Reported balance After 2021-10-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-10-26 · Conversion · Disposed 226,941 · Balance 0 F1: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc. F3: The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc.

F3: The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2021 Filed Jun 2, 2021 10:08 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	7,244	$35.55	$257,524.20	Disclosure SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 4 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 952,636 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.01 to $35.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 28, 2021 Filed Jun 2, 2021 10:08 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	2,104	$37.55	$79,005.20	Disclosure SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 3 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,880 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.00 to $37.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 28, 2021 Filed Jun 2, 2021 10:08 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	2,668	$36.40	$97,115.20	Disclosure SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 961,984 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.96. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 28, 2021 Filed Jun 2, 2021 10:08 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	4,133	$35.37	$146,184.21	Disclosure SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,652 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 27, 2021 Filed May 28, 2021 10:11 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	2,279	$37.55	$85,576.45	Disclosure SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 4 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,785 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.34 to $37.92. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 27, 2021 Filed May 28, 2021 10:11 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	6,174	$36.99	$228,376.26	Disclosure SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 3 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,064 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.35 to $37.33. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 26, 2021 Filed May 28, 2021 10:11 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	4,889	$36.92	$180,501.88	Disclosure SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,238 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.72 to $37.22. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 26, 2021 Filed May 28, 2021 10:11 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	7,469	$36.45	$272,245.05	Disclosure SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,127 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.71 to $36.70. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 25, 2021 Filed May 26, 2021 13:42 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	548	$36.59	$20,051.32	Disclosure SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 4 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 989,596 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.50 to $36.72. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 25, 2021 Filed May 26, 2021 13:42 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	10,399	$36.16	$376,027.84	Disclosure SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 3 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 990,144 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.62 to $36.46. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 24, 2021 Filed May 26, 2021 13:42 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	1,683	$36.10	$60,756.30	Disclosure SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,543 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.33. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 24, 2021 Filed May 26, 2021 13:42 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	8,911	$35.58	$317,053.38	Disclosure SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002,226 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.01 to $35.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 21, 2021 Filed May 24, 2021 10:24 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	11,648	$35.74	$416,299.52	Disclosure SEC source: 0001395064-21-000087 · wf-form4_162185185710054.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,137 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.21 to $36.14. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 20, 2021 Filed May 24, 2021 10:24 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	7,098	$35.10	$249,139.80	Disclosure SEC source: 0001395064-21-000087 · wf-form4_162185185710054.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022,785 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.33. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 14, 2021 Filed May 18, 2021 10:02 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	100	$35.00	$3,500.00	Disclosure SEC source: 0001395064-21-000082 · wf-form4_162133212133123.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,883 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. Read SEC document
May 13, 2021 Filed May 14, 2021 10:04 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	100	$35.33	$3,533.00	Disclosure SEC source: 0001395064-21-000078 · wf-form4_162098662739246.xml · nonDerivative · entry 3 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,983 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. Read SEC document
May 12, 2021 Filed May 14, 2021 10:04 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	905	$36.06	$32,634.30	Disclosure SEC source: 0001395064-21-000078 · wf-form4_162098662739246.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,083 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.18. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 12, 2021 Filed May 14, 2021 10:04 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	10,871	$35.39	$384,724.69	Disclosure SEC source: 0001395064-21-000078 · wf-form4_162098662739246.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,988 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.98. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 07, 2021 Filed May 11, 2021 10:30 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	1,011	$35.03	$35,415.33	Disclosure SEC source: 0001395064-21-000076 · wf-form4_162072902653681.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041,859 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.10. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 06, 2021 Filed May 7, 2021 11:22 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	202	$35.01	$7,072.02	Disclosure SEC source: 0001395064-21-000060 · wf-form4_162038652477240.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042,870 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.03. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 05, 2021 Filed May 7, 2021 11:22 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	6,936	$35.14	$243,731.04	Disclosure SEC source: 0001395064-21-000060 · wf-form4_162038652477240.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,072 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.91. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 04, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	100	$38.53	$3,853.00	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 7 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,008 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. Read SEC document
May 04, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	3,500	$37.47	$131,145.00	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 6 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,108 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F7 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.04 to $37.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 04, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	4,690	$36.21	$169,824.90	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 5 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,608 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F6 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.93. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 04, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	11,070	$35.50	$392,985.00	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 4 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,298 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 03, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	203	$39.06	$7,929.18	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 3 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,368 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $38.96 to $39.16. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 03, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	11,272	$38.45	$433,408.40	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 2 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,571 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $38.04 to $38.92. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
May 03, 2021 Filed May 5, 2021 12:26 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	3,157	$37.60	$118,703.20	Disclosure SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,843 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021. F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.04 to $38.03. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. Read SEC document
June 30, 2020 Filed Jun 30, 2020 20:24 UTC	Translate Bio, Inc. TBIO · Entity 135439	SaleCommon Stock	6,824,992	$20.68	$141,140,834.56	Disclosure SEC source: 0001395064-20-000122 · wf-form4_159356305111852.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F2 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document
June 03, 2020 Filed Jun 5, 2020 09:52 UTC	Translate Bio, Inc. TBIO · Entity 135439	SaleCommon Stock	40,086	$19.75	$791,698.50	Disclosure SEC source: 0001395064-20-000084 · wf-form4_159136513441728.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,824,992 F1 · price: Weighted average of sales prices. Actual prices range from $19.11 to $20.00. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document
June 02, 2020 Filed Jun 3, 2020 06:08 UTC	Translate Bio, Inc. TBIO · Entity 135439	SaleCommon Stock	5,006	$20.02	$100,220.12	Disclosure SEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 4 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,865,078 F6 · price: Weighted average of sales prices. Actual prices range from $20.00 to $20.05. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document
June 02, 2020 Filed Jun 3, 2020 06:08 UTC	Translate Bio, Inc. TBIO · Entity 135439	SaleCommon Stock	100,389	$19.75	$1,982,682.75	Disclosure SEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 3 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,870,084 F5 · price: Weighted average of sales prices. Actual prices range from $19.05 to $19.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document
June 01, 2020 Filed Jun 3, 2020 06:08 UTC	Translate Bio, Inc. TBIO · Entity 135439	SaleCommon Stock	1,400	$20.53	$28,742.00	Disclosure SEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 2 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,970,473 F4 · price: Weighted average of sales prices. Actual prices range from $20.40 to $20.56. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document
June 01, 2020 Filed Jun 3, 2020 06:08 UTC	Translate Bio, Inc. TBIO · Entity 135439	SaleCommon Stock	107,072	$19.85	$2,125,379.20	Disclosure SEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,971,873 F1 · price: Weighted average of sales prices. Actual prices range from $19.40 to $20.25. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document
October 08, 2019 Filed Nov 22, 2019 06:23 UTC	Ovid Therapeutics Inc. OVID · Entity 5411	PurchaseCommon Stock	2,000,000	$2.50	$5,000,000.00	Disclosure SEC source: 0001395064-19-000083 · wf-form4_157442176475523.xml · nonDerivative · entry 1 TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner MILLENNIUM PHARMACEUTICALS INC · CIK 0001002637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 5,750,000 F1 · ownership.nature: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. F2 · ownership.nature: Takeda Pharmaceutical Company Limited's beneficial ownership of the Issuer's Common Stock is comprised of 1,781,996 shares of Common Stock that it holds directly and 5,750,000 shares of Common Stock held directly by Millennium Pharmaceuticals, Inc., which is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document
May 13, 2019 Filed May 13, 2019 19:52 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	ConversionSeries B Redeemable Convertible Preferred Stock · Derivative	319,731	$0.00	$0.00	Disclosure SEC source: 0001209191-19-029480 · doc4.xml · derivative · entry 3 Takeda Ventures, Inc. · CIK 0001771657 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 319,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document
May 13, 2019 Filed May 13, 2019 19:52 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	ConversionSeries A Redeemable Convertible Preferred Stock · Derivative	2,360,071	$0.00	$0.00	Disclosure SEC source: 0001209191-19-029480 · doc4.xml · derivative · entry 2 Takeda Ventures, Inc. · CIK 0001771657 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,360,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document
May 13, 2019 Filed May 13, 2019 19:52 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	ConversionCommon Stock	2,679,802	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-029480 · doc4.xml · nonDerivative · entry 1 Takeda Ventures, Inc. · CIK 0001771657 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,679,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock. F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document
March 19, 2018 Filed Mar 21, 2018 21:42 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	7,420,625	$18.67	$138,543,068.75	Disclosure SEC source: 0000899243-18-008309 · doc4.xml · nonDerivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda A/S · CIK 0001716380 · 10% owner Takeda Europe Holdings B.V. · CIK 0001716379 · 10% owner Takeda Pharma A/S · CIK 0001716226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Millennium Pharmaceuticals , Inc. Disclosed balance after: 7,420,625 F1 · acquired: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · acquired: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · balance_after: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · balance_after: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · ownership.nature: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · ownership.nature: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. Read SEC document
March 19, 2018 Filed Mar 21, 2018 21:42 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Stock	7,420,625	$18.67	$138,543,068.75	Disclosure SEC source: 0000899243-18-008309 · doc4.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda A/S · CIK 0001716380 · 10% owner Takeda Europe Holdings B.V. · CIK 0001716379 · 10% owner Takeda Pharma A/S · CIK 0001716226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · acquired: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · balance_after: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · balance_after: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.